XRN2 and breast carcinoma: First, we evaluated the sensitivity of XRN2-deficient lung and breast cancer cells against these clinically relevant PARP inhibitors and then delineated the cellular consequences of simultaneous XRN2 deficiency and loss of PARP1 catalytic function.